CRISPR-Cas13a mediated targeting of hepatitis C virus internal-ribosomal entry site (IRES) as an effective antiviral strategy-Reference-Cited by-同舟云学术

CRISPR-Cas13a mediated targeting of hepatitis C virus internal-ribosomal entry site (IRES) as an effective antiviral strategy

Published:2021-04 Issue: Volume:136 Page:111239
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Ashraf Muhammad Usman^ORCID,Salman Hafiz Muhammad,Khalid Muhammad Farhan,Khan Muhammad Haider Farooq^ORCID,Anwar Saima,Afzal Samia,Idrees Muhammad,Chaudhary Safee Ullah^ORCID

Funder

Higher Education Commision, Pakistan

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference54 articles.

1. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013;Stanaway;Lancet,2016

2. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden;Younossi;Gastroenterology,2016

3. Hepatitis C virus as a systemic disease: reaching beyond the liver;Gill;Hepatol. Int.,2016

4. Eliminate hepatitis: WHO, (n.d.). https://www.who.int/news-room/detail/27-07-2017-eliminate-hepatitis-who (accessed April 25, 2020).

5. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study;Blach;Lancet Gastroenterol. Hepatol.,2017

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Suppression of Borna Disease Virus Replication during Its Persistent Infection Using the CRISPR/Cas13b System;International Journal of Molecular Sciences;2024-03-20

2. Harnessing CRISPR technology for viral therapeutics and vaccines: from preclinical studies to clinical applications;Virus Research;2024-03

3. Genetic Editing with CRISPR Cas9: recent Biomedical and Biotechnological Applications;Universitas Scientiarum;2024-03-01

4. CRISPR/Cas-based diagnosis and treatment of infectious diseases;Molecular Medical Microbiology;2024

5. Advances in CRISPR/Cas systems-based cell and gene therapy;Progress in Molecular Biology and Translational Science;2024